(A) Agilent Technologies - Overview
Sector: Healthcare | Industry: Diagnostics & Research | Exchange: NYSE (USA) | Market Cap: 32.488m USD | Total Return: 4.3% in 12m
Avg Turnover: 241M
EPS Trend: -38.2%
Qual. Beats: -1
Rev. Trend: -6.9%
Qual. Beats: 0
Warnings
No concerns identified
Tailwinds
No distinct edge detected
Agilent Technologies, Inc. delivers application-specific solutions across the life sciences, diagnostics, and applied chemical sectors. The company’s operations are divided into three primary segments: Life Sciences and Diagnostics, Agilent CrossLab, and Applied Markets. Its portfolio includes liquid chromatography systems, mass spectrometry, genomics tools, and laboratory software designed to manage complex scientific data and workflows.
The business model emphasizes recurring revenue through the CrossLab segment, which provides essential consumables, maintenance services, and software-as-a-service (SaaS) to global laboratories. This integration of hardware and aftermarket services is a standard industry strategy to mitigate the cyclicality of capital equipment sales. The Life Sciences Tools & Services sector is characterized by high barriers to entry due to the specialized engineering and regulatory compliance required for diagnostic and pharmaceutical research.
For more detailed fundamental data, consider reviewing the latest metrics on ValueRay.
Headquartered in Santa Clara, California, Agilent maintains a global distribution network utilizing direct sales, resellers, and e-commerce channels. The company supports diverse end-markets, including clinical diagnostics, environmental testing, and food safety, positioning it as a critical infrastructure provider for scientific research and industrial quality control.
- Biopharma capital expenditure levels dictate demand for liquid chromatography and mass spectrometry systems
- Recurring revenue from CrossLab services and consumables provides margin stability during downturns
- Recovery of analytical instrument sales in the Chinese chemical and environmental markets
- Growth in genomics and nucleic acid manufacturing capacity drives long-term diagnostic revenue
| Net Income: 1.29b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.08 > 0.02 and ΔFCF/TA -3.26 > 1.0 |
| NWC/Revenue: 33.70% < 20% (prev 34.26%; Δ -0.56% < -1%) |
| CFO/TA 0.11 > 3% & CFO 1.40b > Net Income 1.29b |
| Net Debt (1.60b) to EBITDA (1.82b): 0.88 < 3 |
| Current Ratio: 2.07 > 1.5 & < 3 |
| Outstanding Shares: last quarter (284.0m) vs 12m ago -1.05% < -2% |
| Gross Margin: 52.23% > 18% (prev 0.54%; Δ 5.17k% > 0.5%) |
| Asset Turnover: 57.14% > 50% (prev 54.83%; Δ 2.31% > 0%) |
| Interest Coverage Ratio: 14.14 > 6 (EBITDA TTM 1.82b / Interest Expense TTM 109.0m) |
| A: 0.19 (Total Current Assets 4.62b - Total Current Liabilities 2.23b) / Total Assets 12.8b |
| B: 0.12 (Retained Earnings 1.48b / Total Assets 12.8b) |
| C: 0.12 (EBIT TTM 1.54b / Avg Total Assets 12.4b) |
| D: 0.22 (Book Value of Equity 1.30b / Total Liabilities 5.91b) |
| Altman-Z'' = 2.67 = A |
| DSRI: 1.06 (Receivables 1.52b/1.33b, Revenue 7.07b/6.53b) |
| GMI: 1.03 (GM 52.23% / 53.97%) |
| AQI: 0.95 (AQ_t 0.48 / AQ_t-1 0.50) |
| SGI: 1.08 (Revenue 7.07b / 6.53b) |
| TATA: -0.01 (NI 1.29b - CFO 1.40b) / TA 12.8b) |
| Beneish M = -2.93 (Cap -4..+1) = A |
As of May 27, 2026, the stock is trading at USD 115.08 with a total of 1,922,901 shares traded.
Over the past week, the price has changed by +2.65%,
over one month by -0.47%,
over three months by -4.65% and
over the past year by +4.28%.
Agilent Technologies has received a consensus analysts rating of 4.41. Therefore, it is recommended to buy A.
- StrongBuy: 10
- Buy: 4
- Hold: 3
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 161.1 | 40% |
P/E Trailing = 25.3775
P/E Forward = 19.3424
P/S = 4.5984
P/B = 4.7029
P/EG = 1.2021
Revenue TTM = 7.07b USD
EBIT TTM = 1.54b USD
EBITDA TTM = 1.82b USD
Long Term Debt = 3.05b USD (from longTermDebt, last quarter)
Short Term Debt = 304.0m USD (from shortTermDebt, last quarter)
Debt = 3.35b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 1.60b USD (calculated: Debt 3.35b - CCE 1.76b)
Enterprise Value = 34.1b USD (32.5b + Debt 3.35b - CCE 1.76b)
Interest Coverage Ratio = 14.14 (Ebit TTM 1.54b / Interest Expense TTM 109.0m)
EV/FCF = 34.32x (Enterprise Value 34.1b / FCF TTM 993.0m)
FCF Yield = 2.91% (FCF TTM 993.0m / Enterprise Value 34.1b)
FCF Margin = 14.06% (FCF TTM 993.0m / Revenue TTM 7.07b)
Net Margin = 18.26% (Net Income TTM 1.29b / Revenue TTM 7.07b)
Gross Margin = 52.23% ((Revenue TTM 7.07b - Cost of Revenue TTM 3.38b) / Revenue TTM)
Gross Margin QoQ = 52.61% (prev 51.80%)
Tobins Q-Ratio = 2.66 (Enterprise Value 34.1b / Total Assets 12.8b)
Interest Expense / Debt = 3.25% (Interest Expense 109.0m / Debt 3.35b)
Taxrate = 16.21% (59.0m / 364.0m)
NOPAT = 1.29b (EBIT 1.54b * (1 - 16.21%))
Current Ratio = 2.07 (Total Current Assets 4.62b / Total Current Liabilities 2.23b)
Debt / Equity = 0.49 (Debt 3.35b / totalStockholderEquity, last quarter 6.91b)
Debt / EBITDA = 0.88 (Net Debt 1.60b / EBITDA 1.82b)
Debt / FCF = 1.61 (Net Debt 1.60b / FCF TTM 993.0m)
Total Stockholder Equity = 6.54b (last 4 quarters mean from totalStockholderEquity)
RoA = 10.43% (Net Income 1.29b / Total Assets 12.8b)
RoE = 19.73% (Net Income TTM 1.29b / Total Stockholder Equity 6.54b)
RoCE = 16.07% (EBIT 1.54b / Capital Employed (Equity 6.54b + L.T.Debt 3.05b))
RoIC = 14.15% (NOPAT 1.29b / Invested Capital 9.12b)
WACC = 9.07% (E(32.5b)/V(35.8b) * Re(9.72%) + D(3.35b)/V(35.8b) * Rd(3.25%) * (1-Tc(0.16)))
Discount Rate = 9.72% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -90.80 | Cagr: -1.38%
[DCF] Terminal Value 70.46% ; FCFF base≈1.12b ; Y1≈982.7m ; Y5≈794.0m
[DCF] Fair Price = 34.69 (EV 11.4b - Net Debt 1.60b = Equity 9.80b / Shares 282.6m; r=9.07% [WACC]; 5y FCF grow -15.0% → 2.50% )
EPS Correlation: -38.18 | EPS CAGR: -1.48% | SUE: -3.92 | # QB: -1
Revenue Correlation: -6.88 | Revenue CAGR: -0.24% | SUE: -0.40 | # QB: 0
EPS current Quarter (2026-07-31): EPS=1.50 | Chg30d=+0.00% | Revisions=+33% | Analysts=13
EPS current Year (2026-10-31): EPS=5.97 | Chg30d=+0.00% | Revisions=+25% | GrowthEPS=+6.8% | GrowthRev=+6.4%
EPS next Year (2027-10-31): EPS=6.56 | Chg30d=-0.28% | Revisions=+11% | GrowthEPS=+10.0% | GrowthRev=+6.2%
[Analyst] Revisions Ratio: +33%